Esophageal Squamous Cell Carcinoma
Conditions
Interventions
experimental group:Camrelizumab + albumin paclitaxel + nedaplatin
Sponsors
Anhui Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age: 18~75 years old, no gender limit; 2. Patients with resectable esophageal squamous cell carcinoma confirmed by histopathology or cytology (cT1-3N1-2M0 and cT4aN0-1M0 patients); 3. No previous treatment, including surgery, chemotherapy, radiotherapy, immunotherapy and targeted therapy; 4. ECOG PS score 0-1 points; 5. Estimated survival period >= 6 months; 6. The main organ functions are normal, and there are no patients with severe blood, heart, lung, liver, kidney, bone marrow and other functional abnormalities and immunodeficiency. 7. Laboratory inspection meets the following requirements: (1) Hemoglobin (Hb) >=110 g/L; (2) White blood cell (WBC)>=3.5x10^9/L; Neutrophil count (NEUT)>=1.5x10^9/L; (3) Platelets (PLT) >=100x10^9/L (4) Liver function (aspartate aminotransferase AST or alanine aminotransferase ALT) level <=2.5 times the upper limit of normal (ULN); renal function (serum creatinine sCr) level <=1.5 times the upper limit of normal (ULN); (5) Total bilirubin (TBIL) <= 1.5 times the upper limit of normal (ULN); (6) TSH normal range; if TSH is abnormal, total T3 or free T3, free T4 should be in the normal range; 8. Subjects voluntarily join the study, sign an informed consent form, have good compliance, and cooperate with follow-up; 9. The investigator believes that the treatment can benefit.
Exclusion criteria
Exclusion criteria: 1. Those who have been confirmed to be allergic to the test drug and/or its excipients; 2. Subjects suffering from childhood asthma that have been completely relieved and do not require any intervention or vitiligo after adulthood can be included, and subjects who require medical intervention with bronchodilators cannot be included; 3. Have a history of organ transplantation; 4. Pregnant or lactating women; 5. According to the judgment of the investigator, patients who are not suitable for inclusion in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathological complete remission rate; | — |
Countries
China
Contacts
Public ContactZhang Anqing
Anhui Cancer Hospital
Outcome results
None listed